International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Jun 2012
Clinical TrialFive year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
Accelerated whole-breast radiotherapy (RT) with tumor bed boost in the treatment of early invasive breast cancer has demonstrated equivalent local control and cosmesis when compared with standard RT. Its efficacy in the treatment of ductal carcinoma in situ (DCIS) remains unknown. ⋯ With a median follow-up of 5 years, the ipsilateral local recurrence rate is 4.1%, comparable to that reported from the NSABP (National Surgical Adjuvant Breast and Bowel Project) trials that employed 50 Gy in 25 fractions of radiotherapy for DCIS. There were no invasive recurrences. These results provide preliminary evidence that accelerated hypofractionated external beam radiotherapy is a viable option for DCIS.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jun 2012
Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer.
To investigate the feasibility of diffusion-weighted MRI (DWI) as an early and reproducible change indicator in patients receiving radiotherapy for prostate cancer (PC). ⋯ DWI, as a reproducible biomarker, has the potential to evaluate the early therapeutic changes of PC to radiotherapy.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jun 2012
Comparative StudyClinical application of a novel hybrid intensity-modulated radiotherapy technique for stage III lung cancer and dosimetric comparison with four other techniques.
In large stage III lung tumors, planning delivery of doses exceeding 60 Gy can be challenging and time consuming. Intensity modulated radiation therapy (IMRT) can improve target coverage but may increase volumes receiving low-dose irradiation. We clinically implemented a novel hybrid IMRT (h-IMRT) technique that allowed plans to be produced quickly, and compared these plans with 4 other techniques. ⋯ Both h-IMRT and h-RapidArc permitted delivery of 66 Gy to large stage III lung tumors, and both were superior to either full IMRT or RapidArc plans for reducing lung doses. The clinical significance of small increases in V(5) during chemo-radiation therapy delivery are unknown, but the present study suggests that h-IMRT and h-RapidArc are preferable for treatment of large tumors.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jun 2012
Early proctoscopy is a surrogate endpoint of late rectal toxicity in prostate cancer treated with radiotherapy.
To predict the grade and incidence of late clinical rectal toxicity through short-term (1 year) mucosal alterations. ⋯ Early proctoscopy (1 year) predicts late rectal bleeding and therefore can be used as a surrogate endpoint for late rectal toxicity in studies aimed at reducing this frequent complication.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jun 2012
Predictors of metastatic disease after prostate brachytherapy.
To identify predictors of metastatic disease after brachytherapy treatment for prostate cancer. ⋯ GS and post-treatment PSA-DT are both statistically significant independent predictors of metastatic disease. Patients with a high GS and/or short PSA-DT have a higher likelihood of developing metastatic disease and should be considered for systemic therapy.